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Background: National estimates for the occurrence of diabetes are difficult to obtain, particularly time trends in
incidence. The aim was to describe time trends in prevalent and incident use of blood glucose-lowering drugs by
age group and gender in Norway during 2005–2011.
Methods: Data were obtained from the nationwide Norwegian Prescription Database. We defined prevalent
users of “insulins only” as individuals having no oral antidiabetic drugs (OAD) dispensed from a pharmacy
during the previous 24 months or in the subsequent 12 months. Incident users had no blood glucose-lowering
drugs dispensed in the previous 24 months; incident “insulins only” users also had no OAD in the subsequent
12 months.
Results: In 2011, 3.2% of the population had blood glucose-lowering drugs dispensed, and the incidence rate was
313 per 100,000 person years. The prevalence of OAD use increased from 1.8% in 2005 to 2.4% in 2011; however a
decreasing trend in incidence of OAD use was observed, particularly in those aged 70 years and older. In 2010, 0.64%
of the population had insulins only dispensed, with an overall incidence rate in the total population of 33 per 100,000
person years which was stable over time.
Conclusions: In this nationwide study, we found that although the prevalent use of OAD had increased in recent
years, incident use was stable or had decreased. This may indicate that the increase in diabetes occurrence in Norway
is levelling off, at least temporarily.
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Diabetes constitutes a major public health challenge and
numerous studies suggest that the prevalence is increasing
in most countries [1]. However, reliable national estimates
for the occurrence of diabetes are difficult to obtain,
particularly time trends in incidence. Population-based
health studies have limitations, since study samples tend
to have low and therefore potentially biased participation
[2,3]. A few countries such as Denmark, Sweden and
Scotland have established national diabetes registers to* Correspondence: hanne.strom@fhi.no
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unless otherwise stated.monitor trends in the occurrence of diabetes [4,5], but few
of these have complete coverage.
While most approaches to estimating the total number
with diagnosed diabetes in a population are likely to
have important sources of error, data from nationwide
prescription drug databases can overcome the problems
with biased participation and limited sample sizes to
estimate gender- and age-specific trends. All diagnosed
patients with Type 1 diabetes and a large majority of
patients with Type 2 diabetes in most Western countries
are treated with blood glucose-lowering drugs. In European
children, insulin use essentially indicates a diagnosis of
Type 1 diabetes [6].
Blood glucose-lowering drugs are used for other
indications than diabetes, e.g. metformin for thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow chart illustrating the definitions used for classifying subjects as (a) prevalent and (b) incident users of any blood
glucose-lowering drug, OAD and insulins only. Figures for 2010 are shown.
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http://www.biomedcentral.com/1471-2458/14/520treatment of polycystic ovary syndrome (PCOS) and this
has to be taken into account. Furthermore, diabetes
not treated with blood glucose-lowering drugs and
undiagnosed diabetes will not be covered but important
trends can nevertheless be monitored with high quality
population-based prescription databases [7].
The primary aim of this study was to describe time trends
in prevalent and incident use of blood glucose-loweringdrugs by age group and gender in Norway during
2005–2011.
Methods
Data sources
The Norwegian Prescription Database (NorPD) was estab-
lished in 2004 and includes all prescriptions redeemed by
individual patients (encrypted) at pharmacies. Information
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Figure 2 Prevalent use of blood glucose-lowering drugs by age and gender in Norway in 2010. Solid lines: any blood glucose-lowering
drug (A10). Dashed lines, oral antidiabetic drugs. Short dashed lines: insulins only; i.e. individuals having insulins dispensed in 2010, but no OAD in
the previous 24 months or in the subsequent 12 months after the first prescription filled.
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not on an individual level. NorPD covers drug supply for
the entire population of Norway (4.92 million inhabitants
in 2011). All pharmacies are obliged by law to report
data electronically to the NorPD each month [8]. Blood
glucose-lowering drugs are classified in the Anatomical
Therapeutic Chemical (ATC) classification system in group
A10. Insulins and analogues are classified in A10A, while
other blood glucose-lowering drugs, referred to here as oral
antidiabetic drugs (OAD), are classified in A10B [9,10].
Research was part of the mandate sanctioned by the
Norwegian Data Protection Authority when the NorPD
was established. Permission to conduct this descriptive
study was therefore not required from the Regional
Committee for Medical Research Ethics.Study population
The size of the population by gender and age in each
calendar year studied was obtained from Statistics
Norway. The analyses were based on data from NorPD
about drugs prescribed and dispensed from 1 January 2004
to 31 December 2011. Data from 2004 were included to
allow for a run-in period. Treatment with blood glucose-
lowering drugs was used as a proxy for drug-treated
diabetes.Outcome measures
Figure 1 illustrates the definitions used for classify-
ing subjects as (a) prevalent and (b) incident users
of any blood glucose-lowering drug, OAD and insu-
lins only.(a)Prevalence outcome measures
Individuals with at least one prescription of any blood
glucose-lowering drug dispensed in a calendar year were
counted as prevalent users. Individuals with at least one
OAD prescription alone or in combination with insulins
dispensed in a calendar year were counted as prevalent
users of OAD. Individuals with at least one prescription
of insulins dispensed in a calendar year but no OAD in
the periods 24 months prior to or 12 months after their
first insulin prescription was dispensed were counted as
prevalent users of insulins only.
(b)Incidence outcome measures
Incident users of blood glucose-lowering drugs were
defined as individuals having at least one prescription of
these drugs dispensed in a calendar year but not in the
24 months period prior to the first prescription. Incident
users of OAD were defined as individuals having at least
one prescription of OAD dispensed in a calendar year or
period but no blood glucose-lowering drugs in the previous
24 months. Incident users of insulins only were defined
as individuals having at least one prescription of insulin
dispensed in a calendar year or period but no blood
glucose-lowering drugs in the previous 24 months, and no
OAD in the subsequent 12 months.Statistical methods
Person years for calculation of incidence rates were
estimated from the mean population size for each
gender, age group and calendar year. Influence of age
and gender and test for trend by calendar year were
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(StataCorp LP, College Station, TX, USA). Incidence rate
ratio (IRR) per year was calculated, and interaction between
calendar year and age was tested by likelihood ratio test.
Results
Prevalent use of blood glucose-lowering drugs
In 2011, 156,540 individuals (3.2% of the population)
had blood glucose-lowering drugs dispensed compared
to 117,541 individuals (2.5% of the population) in 2005.
As expected, the prevalence increased strongly with age.
The prevalence was higher in men than in women after
40 years of age. The peak prevalence in men was at age
76 years (12.4%) and in women at age 80 years (9.9%), a
pattern very similar to that of users of OAD (Figure 2).0
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Figure 3 Time trends in prevalence of OAD (A10B) use by 10 year agThe prevalence of OAD use increased from 1.8% in
2005 to 2.4% in 2011 and there was an increase in all
age groups, with a larger increase in men than in women
(Figure 3).
In 2010, 31,515 individuals (0.64% of the population) had
insulins only dispensed and the prevalence was stable
during the period 2006–2010 (data not shown). In a sensi-
tivity analysis we calculated the prevalent users of insulins
only by extending the period without previous use of OAD
up to six years. With a six year period, the number
declined to 27,927 (0.57%) (Additional file 1: Table S1).
Incident use of blood glucose-lowering drugs
The incidence of OAD use was significantly higher in
women than in men aged 20–39 years and the pattern90+0-69 70-79 80-89
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Figure 4 Incident use of blood glucose-lowering drugs by age and gender in Norway. Incident use is defined as no use of blood
glucose-lowering drugs in the previous 24 months. (a) OAD (A10B); period 2006–2011. (b) Insulins and analogues (A10A); period 2006–2010.
No OAD dispensed in the subsequent 12 months.
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the overall incidence rate was significantly lower than
the previous year (Table 1). The decreasing incidence of
OAD use during the study period was largely confined
to the 70 years or older age group (IRR per year = 0.97
(95% CI 0.96-0.98) in men and IRR = 0.95 (95% CI 0.94-0.96)
in women) but a weaker significant decreasing trend
was also observed for those aged 50–69 years (IRR per
year = 0.99 (95% CI 0.98-1.00) in men and IRR = 0.98
(95% CI 0.97-0.99) in women) (Figures 5a-b).
In women, the highest incidence of insulin use only
was in the 30–39 year age group, and for men it was
highest among the 70–79 year age group (Figure 4b).
In a sensitivity analysis, 59% of incident insulins onlyusers among women aged 30–39 years in 2008 had
stopped insulin treatment within the following two
years, indicating gestational diabetes rather than Type 1
diabetes (Additional file 2: Figure S1). There was no
significant overall time trend in incident use of insulins
only for men (IRR per year = 1.01 (95% CI (0.98-1.03) but
a weak increasing overall trend for women was observed
(IRR per year = 1.03 (1.01-1.05) (Figures 5c-d).
Supplementary material
Detailed data tabulated by age group, gender and calendar
year are provided in Additional file 1: Table S2-S5.
Population sizes used to calculate incidence and prevalence
are shown in Additional file 1: Table S6.
Table 1 Incident users of any blood glucose-lowering drug, oral antidiabetic drugs (OAD) and insulins only*
Any blood glucose-lowering drug (A10) OAD (A10B) Insulins only (A10A only)
Year Person
years
No of
patients
Incidence rate
per 100,000
person years
95%
confidence
interval
No of
patients
Incidence rate
per 100,000
person years
95%
confidence
interval
No of
patients
Incidence rate
per 100,000
person years
95%
confidence
interval
Women
2006 2,347,036 7,531 320 (314, 328) 6,752 288 (281, 295) 670 29 (26, 31)
2007 2,366,461 7,769 328 (321, 336) 6,927 293 (286, 300) 679 29 (27, 31)
2008 2,390,716 7,677 321 (314, 328) 6,717 281 (274, 288) 783 33 (31, 35)
2009 2,418,595 7,832 323 (317, 331) 6,912 286 (279, 293) 745 31 (29, 33)
2010 2,445,249 7,778 318 (311, 325) 6,817 279 (272, 286) 784 32 (30, 34)
2011 2,473,228 7,269 293 (287, 301) 6,369 258 (251, 264) †
Men
2006 2,314,006 7,829 338 (331, 346) 6,830 295 (288, 302) 756 33 (30, 35)
2007 2,342,823 8,374 357 (350, 365) 7,326 313 (306, 320) 793 34 (32, 36)
2008 2,377,361 8,655 364 (356, 372) 7,498 315 (308, 323) 845 36 (33, 38)
2009 2,411,205 8,620 357 (350, 365) 7,453 309 (302, 316) 839 35 (33, 37)
2010 2,443,697 8,605 352 (345, 360) 7,475 306 (299, 313) 813 33 (31, 36)
2011 2,479,989 8,246 332 (325, 340) 7,131 288 (281, 294) †
Total
2006 4,661,041 15,360 329 (324, 334) 13,582 291 (287, 297) 1,426 31 (29, 32)
2007 4,709,284 16,143 342 (338, 348) 14,253 303 (298, 308) 1,472 31 (30, 33)
2008 4,768,077 16,332 342 (337, 348) 14,215 298 (293, 303) 1,628 34 (33, 36)
2009 4,829,800 16,452 340 (335, 346) 14,365 297 (293, 302) 1,584 33 (31, 34)
2010 4,888,946 16,383 335 (330, 340) 14,292 292 (288, 297) 1,597 33 (31, 34)
2011 4,953,217 15,515 313 (308, 318) 13,500 273 (268, 277) †
*Incident use is defined as no use of blood glucose-lowering drugs in the previous 24 months. In addition, for insulins only no OAD was dispensed in the
subsequent 12 months.
†For insulins only users there are no data for 2011 due to the definition applied, requiring a 12 month follow up period after first insulin prescription filled.
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We have monitored the use of blood glucose-lowering
drugs in Norway, and found an increase in the overall
prevalence from 2.5% in 2005 to 3.2% in 2011. Interestingly,
the number of new users was, for the first time in the
period, significantly lower in 2011 than the year before and
this was primarily due to a reduction in incident use of
OAD in the 70 years and older age groups.
The prevalence of diabetes depends on the incidence
and mean duration of the disease, both of which are
affected by several factors. For example, increased
survival among those with the diagnosis will increase the
prevalence [11] and higher life expectancy (ageing) in
the general population could influence the incidence.
Others have shown that declining mortality among
patients may contribute, but that increasing incidence
was the main driver of the increasing prevalence over
time, at least in Denmark 1992–2003 [7] and in Scotland
1993–2004 [5]. We did not have mortality data in our
study but others have shown a secular decrease in
mortality from ischaemic heart disease among patientswith diabetes in Norway [12], suggesting that this
could have contributed to the observed increasing
prevalence with concurrent decline in incidence.
The strength of this study is the complete coverage of
the Norwegian population [8]. NorPD should therefore
provide good estimates for the number of patients
with diabetes treated with blood glucose-lowering
drugs (100% reimbursed), with a few caveats that are
discussed below. The study does not cover diabetes that is
not treated with blood glucose-lowering medication, and
classification of diabetes into Type 1 or Type 2 diabetes
based on available data is difficult in the older age
groups. Individuals with at least one prescription of
blood glucose-lowering drugs dispensed were included
but the vast majority had actually had several pre-
scriptions. In 2010, of incident users in both groups
(insulins only and OAD) recorded, 88% redeemed
more than one prescription during the following 12
months. Institutionalisation, emigration, switch to lifestyle
treatment only, or off-label use (PCOS, obesity) could
partly confound the results (see below). The high incident
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Figure 5 Time trends in incident use of blood glucose-lowering drugs in Norway. Incident defined as no use of blood glucose-lowering
drugs in the previous 24 months. In addition for incident use of insulins only, no OAD dispensed in the subsequent 12 months. (a) Incident use of
OAD (A10B) in men (b) Incident use of OAD in women. (c) Incident use of insulins only (A10A) in men (d) Incident use of insulins only in women.
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be explained by gestational diabetes.
Another limitation is lack of individual level data of
institutionalised patients with diabetes. About 13% of
the population above 80 years of age (approximately
30,000 people) lived in nursing homes in Norway in
2011 (figures from Statistics Norway, www.ssb.no). Thus,
the prevalence and incidence in the oldest patient groups
will be underestimated. For instance, recalculating for
users of blood glucose-lowering drugs in 2011, the preva-
lence increased from 9.0% to 10.4% in the over 80 age
group. However, data from the NorPD show that in 2011
only 2.4% of total DDDs (Defined Daily Doses) [10] pre-
scribed of blood glucose-lowering drugs were dispensed to
institutions. For insulins, 3.4% of total DDDs prescribed
were dispensed to institutions. This is probably too little to
have any major influence on our observed time trends.
Migration of patients has not been taken into account
in the study. In principle, a prevalent user of blood
glucose-lowering drugs, moving from another country to
Norway, may therefore have been mistakenly counted as
an incident user. Again, this is likely to be a minor
source of error, particularly for time trends.
The use of dispensed drugs in a prescription database
as a proxy for diabetes will obviously result in an under-
estimation of the total number of patients with diabetes
in the population, as a considerable proportion of Type
2 diabetes patients are treated with lifestyle measuresalone. Studies from Norway in the period 1995–2005
report that 20-35% of prevalent patients are treated
by diet only [13-15]. Data from 33 general practices
in two representative areas of Norway showed a
decline in the proportion of patients with diabetes
not treated with blood glucose-lowering drugs, from
30.7% in 1995 to 28.4% in 2005 [14]. Data from the
Swedish Diabetes Register show a decline in the pro-
portion of patients with Type 2 diabetes treated with
diet only from 25.3% in 2008 to 23.4% in 2011 [16]. We
do not have nationally representative data on the pro-
portion of diabetes patients not treated with blood
glucose-lowering medication for our study period
(2005–2011) but if there is a real decline in this pro-
portion, it is particularly interesting that the incident
use of blood glucose-lowering drugs did not increase
during the study period. The proportion of patients
not treated may also be influenced by the number of
new blood glucose-lowering drugs available on the
market promoted by the pharmaceutical industry.
On the other hand, we cannot rule out the possibility
that the proportion of diagnosed Type 2 diabetes patients
treated with OAD has declined during the study period;
for instance, as a result of patients being diagnosed earlier
and increasing focus on beneficial dietary changes.
Safety concerns in the elderly regarding polypharmacy
and hypoglycaemic episodes could also contribute to
such a trend.
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have Type 2 diabetes. On the other hand, there will be
some misclassification from prescriptions for patients with
PCOS, pre-diabetes and the metabolic syndrome [17-19].
Some women of reproductive age who are treated with
metformin are probably suffering from PCOS rather than
diabetes. In 2011, the total number of women in this age
group treated with metformin was 3,482 (0.54% in this age
group population), and a total of 3,712 (0.58%) received oral
blood glucose-lowering drugs. In European studies, the
occurrence of PCOS has been reported to be 6.5-8% [20].
Since insulins and analogues are used by both patients
with Type 1 diabetes and Type 2 diabetes, the definition
applied in the outcome measure “prevalent user of insulins
only” is aimed at estimating a group of patients with Type
1 diabetes. Some of the defined insulins only users may
have received treatment with OAD prior to the 24 month
period, as suggested in our sensitivity analysis that extends
the period to six years. This could be explained by switch-
ing from OAD to insulins only e.g. due to the relative
contraindication of OAD in severe heart and kidney failure.
Thus, the estimated prevalence of Type 1 diabetes in
the population in this study may be overestimated to
some extent in the elderly.
There was a stable incidence of use of insulins only.
Recent data on childhood-onset Type 1 diabetes from
the Norwegian Childhood Diabetes Registry show little
or no increase in the past few years, which is consistent
with the current results [6]. In the only previous Norwegian
study of Type 1 diabetes incidence in individuals over 15
years of age from Norway, Joner & Søvik estimated
an incidence of 17/100,000 person years in the age
group 15–29 years during 1978–1982 [21]. The current
study showed 32/100,000 person years across all age
groups. In the age groups over 30–40 years, diabetes
classification becomes more challenging. It is nevertheless
clear that a substantial proportion of incident Type 1
diabetes cases arise in adulthood [22].
Conclusions
There was no increase in the incident use of blood glucose-
lowering drugs in Norway in the period 2006–2011 and
there was even a decline in the incident use of OAD, par-
ticularly in those aged 70 years and older. This occurred
despite an increase in prevalent use of OAD. The prevalence
and incidence of insulin use only was stable during the study
period. This may indicate that the increase in diabetes
occurrence in Norway is levelling off, at least temporarily.
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